Aegros Ltd

Aegros’s HaemaFrac® is a groundbreaking membrane-based tangential flow preparative electrophoresis process that revolutionizes plasma fractionation technologies. Unlike traditional ethanol-based methods, HaemaFrac® offers a single-step, scalable solution that achieves higher yield, purity, and process efficiency while eliminating the need for multiple steps and solvents. This innovative technology enables the isolation of plasma proteins in their native state and the simultaneous removal of viruses, representing a significant advancement for the industry.

With the blood and plasma industry dominated by long-standing technologies from CSL, Grifols, and Takeda, Aegros aims to disrupt the market with the HaemaFrac® machine and process. Aegros’ solution not only achieves higher yields from smaller batch sizes but also operates significantly faster, leading to reduced COGS. This increased efficiency enables countries to establish domestic fractionation industries, enhancing self-sufficiency.

Aegros is developing Covimmune™, a hyperimmune against Covid-19, as our first product.

Extensive research and clinical trials are being undertaken because it is vital that this new treatment option against Covid-19 takes its place among the medicines that have already been developed.